Weight & metabolism

Tirzepatide

Zepbound, Mounjaro

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro). It is backed by large, multi-year clinical trial programs.

Key facts

  • Commonly discussed for: weight management and type 2 diabetes.
  • Evidence (A): SURMOUNT-1 randomized 2,539 adults and found 15% to 20.9% average weight loss at 72 weeks across doses versus 3.1% with placebo, within a larger phase 3 program.
  • FDA status: FDA-approved. FDA approved Zepbound for chronic weight management on November 8, 2023, and FDA reports the tirzepatide shortage is resolved.
  • Legitimate access: Rx brand.
  • Last reviewed: October 1, 2026.

Read the deep dives

Sources